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Abstract
Purpose There is an increasing number of patients
being dialyzed with permanent catheters (PC). In the
majority of cases, heparin is used to maintain PC patency.
This practice causes clotting disturbances due to heparin
leakage and may predispose the patient to bleeding
episodes. It has not been well studied whether lowering
heparin concentration for canal locking decreases short-
term bleeding complications after PC placement.
Methods This was a prospective single-center ran-
domized open-label trial conducted in hemodialyzed
patients undergoing PC insertion. Low concentration
of heparin (LCH) 2,500 IU/ml versus high concentration
of heparin (HCH) 5,000 IU/ml was randomly used for
catheter lumens locking. The primary endpoint was the
occurrence of bleeding within 24 h after catheter place-
ment. The effects of clinical and laboratory data on
bleeding events were analyzed as secondary endpoints.
Results Seventy-five patients (37 in LCH) were
enrolled in the study. Only in the HCH group we
found a significant prolongation of activated partial
thromboplastin time (APTT) 2 h after PC placement
(p \ 0.001). There was a higher number of bleeding
episodes in the HCH group (n = 16; 42.1%) than in the
LCH group (n = 7; 18.9%) (v2 = 4.74; p = 0.029).
In univariate analysis, assignment to HCH, baseline
APTT, use of low molecular weight heparin, and
femoral localization were associated with bleeding
events. In multivariate analysis, the use of HCH (odds
ratio [OR] 3.64; 95% confidence interval [95% CI]
1.10–12.05) and baseline APTT (OR 1.12; 95% CI
1.002–1.250) predicted bleeding after PC insertion.
Conclusion LCH used for canals locking decreases
bleeding events in the first 24 hours after permanent
catheter placement, compared to HCH.
Keywords Bleeding  Hemodialysis  Heparin 
Permanent catheter
Introduction
The mainstay of successful hemodialysis therapy
is reliable vascular access. Nowadays, two viable
options exist for hemodialysis patients (HD): arterio-
venous fistula or central venous catheter. The number
of patients dialyzed with a central venous catheter
gradually continues to increase [1, 2], even though
current guidelines unequivocally recommend an arte-
riovenous fistula as the preferred vascular access for
HD [3]. In dialysis centers, up to 80% of HD start renal
replacement therapy with a catheter [4] and in one-
third of them it serves as a long-term vascular access
[5]. Both patient- and nephrologist-related factors are
responsible for this phenomenon [6, 7]. It may be
anticipated that this trend will not reverse in the near
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future, thus nephrologists will be facing patients
needing permanent catheter (PC) insertion more and
more frequently.
PC placement is a relatively safe procedure,
although sometimes it is associated with the develop-
ment of several complications. The spectrum of
possible complications varies from life-threatening
like cardiac tamponade or pneumothorax, to minor
such as a puncture of an artery with a ‘‘finder needle.’’
One of the possible problems often encountered after
PC placement is bleeding from the site of insertion.
It is mainly caused by clotting derangement due to the
leak of heparin from the catheter lumens [8]. The
concentration of heparin instilled into PC canals varies
from 1,000 to 10,000 IU/ml, as there are no guidelines
addressing this problem.
It was shown earlier [9] that heparin concentration
did not adversely affect catheter patency. The aim of
the study was to test a hypothesis that the lower
heparin concentration used for canal locking limits
bleeding episodes in HD after PC insertion.
Subjects and methods
This was a single-center, prospective, randomized,
open-label trial evaluating the influence of heparin
concentration used for permanent catheters canals
locking on frequency of bleeding complications in
HD. Patients were randomized with toss a coin method
into one of two groups, which differed in concentra-
tion of heparin (2,500 IU/ml low concentration of
heparin—LCH vs. 5,000 IU/ml high concentration of
heparin—HCH) used for catheter lumens locking.
All patients received dual lumen cuffed catheters
(Covidien Palindrome, Mansfield, MA, USA). The
catheter insertion took place in a separate room, under
aseptic conditions and local anesthesia (1% lidocaine).
The site of insertion was based on clinical factors and
was left to the operator’s decision. Catheters 14.5
Fr/28 cm in length were placed in the internal jugular
vein or 14.5 Fr/55 cm when femoral vein was used.
Immediately after catheter placement, its patency was
checked and lumens were filled with nominal volume
of heparin at a concentration in accordance with the
assigned group (2,500 or 5,000 IU/ml). The correct
localization of the catheter was confirmed with X-ray.
Before catheter placement, white blood cells
(WBC) and platelet count (PLT), hemoglobin (HGB),
fibrinogen (FBG) concentration, international normal-
ized ratio (INR), and activated partial thromboplastin
time (APTT) were measured with standard laboratory
methods and demographic data were recorded. Two
hours after the procedure, APTT was determined. All
patients were observed for 24 h.
Before entering the study, all patients gave informed
consent. The study was conducted in accordance with
the principles of the Declaration of Helsinki. The
research protocol was reviewed and accepted by a local
ethics committee.
Definitions
The indication for permanent catheter insertion was
classified as: incident renal failure—the catheter was
placed, when there was a need for dialysis initiation
and the patient did not have a-v fistula and prevalent
renal failure—the catheter was inserted in chronically
dialyzed patient with dysfunctional fistula.
The causes of end stage renal disease (ESRD) were
divided into: glomerulonephritis, diabetic nephropa-
thy, autosomal polycystic kidney disease, and others
(unknown, obstructive nephropathy).
Bleeding episode was defined as the need to change
dressings once or more within 24 h after catheter
insertion. After catheter insertion, the site of surgery
was observed for 60 s to assure that there is no
persistent bleeding from the wound.
Statistics
Data are presented as mean ± SD and frequency
percentage for categorical variables.
In 4 cases APTT 2 h after insertion was immea-
surable—blood did not clot. These cases were treated
as APTT equal to 163.7 s—the longest time, which
was measured in the cohort during the study.
Independent or dependent continuous variables
were compared with an appropriate variant of Student
t test. Differences between categorical data were
evaluated with v2 test. For bivariate associations
between bleeding episodes and variables of interest,
logistic regression analysis was used. The variables
associated with endpoint in univariate analysis
(p \ 0.10) were included into multivariate logistic
regression analysis.
A two-tailed p value below 0.05 was considered
significant. All computations were performed with
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Statistica 9.1 for Windows (StatSoft Inc.; Tulsa, OK,
USA).
Results
Seventy-five patients (36 males, 48%) were enrolled in
the study. The mean age of studied population was
64.5 ± 14.5 years. The following were causes of
ESRD in the studied population: glomerulonephritis
(n = 20; 27%), diabetic nephropathy (n = 12; 16%),
autosomal polycystic kidney disease (n = 10; 13%),
and others (n = 33; 44%).
Thirty-eight patients (50.7%) were assigned to the
HCH group. Internal jugular vein was used in 33
(89%) patients in LCH and 31 (82%) in HCH group
(p = 0.35). The catheter was placed on the right side
in 27 (73%) subjects in LCH and 34 (90%) in HCH
(p = 0.06). Demographic and laboratory data of both
groups are presented in Table 1. At baseline, both
groups did not differ significantly in any of evaluated
parameters.
Two hours after the catheter placement, there was
significant prolongation of APTT value only in HCH
group (from 38.5 ± 5.1 to 75.2 ± 41.8 s; p \ 0.001).
In LCH, there was slight non-significant prolongation
of APTT (from 38.3 ± 6.0 to 42.3 ± 17.2 s;
p = 0.17). There was striking difference in APTT
value between LCH and HCH group 2 h after catheter
insertion (42.3 ± 17.2 vs. 75.2 ± 41.8 s; p \ 0.001)
(Fig. 1).
Insertion of catheter into jugular or femoral vein
caused significant prolongation of APTT irrespec-
tively of heparin concentration used for canal locking
(Jugular Vein; from 37.86 ± 5.3 to 48.99 ± 24.7 s;
p = 0.002, Femoral Vein; from 41.06 ± 5.6 to
108.7 ± 51.2; p = 0.001) (Fig. 2).
There was higher number of bleeding episodes in
HCH (16; 42.1%) than in LCH (7; 18.9%) (v2 = 4.74;
p = 0.029). During the study, there were no cases of
catheter thrombosis in either LCH or in HCH.
In univariate logistic regression, the use of LMWH
(v2 = 3.35; p = 0.07), assignment to HCH group
(v2 = 4.55; p = 0.033), femoral localization (v2 =
3.22; p = 0.073), baseline APTT value (v2 = 5.65;
p = 0.02), and APTT 2 h after catheter insertion
(v2 = 9.26; p = 0.002) were associated with bleeding
episodes (Table 2).
As the APTT value 2 h after insertion was the
consequence of group assignment, two multivariate
models were built in which group assignment (Model
1) or APTT value 2 h after insertion (Model 2) was
used as an independent variable. In Model 1
(v2 = 16.85; p = 0.002), group assignment and base-
line APTT value were the only predictors of bleedingTable 1 Characteristic of two analyzed groups
LCH HCH
Subjects (n) 37 38
Female/male 18/19 21/17
DM (n; %) 9; 24 8; 21
Cause of catheter insertion:
incident/prevalent renal
failure
10/27 12/26
Age (years) 64 ± 15 65 ± 14
ASA (n; %) 10; 28 9; 26
LMWH (n; %) 3; 8 3; 8
HGB (g/dl) 10.2 ± 1.9 10.3 ± 1.8
PLT (9103/ll) 215.1 ± 67.5 215.3 ± 99.4
FBG (mg/dl) 431.7 ± 200.7 424.7 ± 203.4
APTT (s) 38.8 ± 5.9 38.9 ± 5.3
INR 1.09 ± 0.11 1.08 ± 0.11
APTT activated partial thromboplastin time, ASA use of
acetylsalicylic acid, FBG fibrinogen, HCH high concentration
of heparin, HGB hemoglobin, INR international normalized
ratio, LCH low concentration of heparin, LMWH use of low
molecular weight heparin, PLT platelet count
Fig. 1 APTT values with regard to heparin concentration used
for catheter canal locking. (*Baseline APTT vs. APTT 2 h after
catheter insertion p \ 0.001, ##comparison of APTT 2 h after
catheter insertion HCH vs. LCH p \ 0.001). APTT activated
partial thromboplastin time, HCH high concentration of heparin,
LCH low concentration of heparin
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occurrence. Model 2 (v2 = 19.86; p = 0.00053)
revealed just APTT value 2 h after insertion as the
independent predictor of bleeding after catheter
insertion (Table 3).
Discussion
According to obtained results, lower heparin concen-
tration decreases the odds of bleeding after PC
insertion. As current guidelines do not give any
recommendations on this subject, results of this study
may give a rationale to routinely use lower heparin
concentration to fill lumens of PC at least just after
insertion. Our results are in line with the retrospective
study by Yevzlin et al. [10], who also showed that
concentrated heparin lock is associated with major
bleeding events after PC placement.
The bleeding tendency in patients with PC results
from coagulation abnormalities due to heparin used for
catheter lumens locking. In our study APTT 2 h after
insertion was prolonged *2 times, if the high concen-
tration of heparin was used. It was reported earlier that
significant APTT prolongation occurs just after 10 min
of canals locking with heparin [11, 12]. The observed
systemic anticoagulation is caused by at least 3 mech-
anisms. Firstly, there are reports showing that real
volume of catheter lumens is often substantially lower
then that reported by the manufacturer [11]. Secondly,
heparin diffuses from catheter canals into systemic
circulation within an hour after placement, and thirdly,
the fast push of the heparin is associated with a higher
degree of clotting abnormalities [8].
Fig. 2 APTT values with regard to the length of catheter used
(*Baseline APTT vs. APTT 2 h after catheter insertion in FV
p \ 0.01, §baseline APTT vs. APTT 2 h after catheter insertion
in JV p \ 0.01, ##comparison of APTT 2 h after catheter
insertion FV vs. JV p \ 0.001) APTT activated partial
thromboplastin time, JV jugular vein, FV femoral vein
Table 2 Results of univariate logistic regression analysis
Univariate analysis
Variable OR 95% CI p
Sex 1.27 0.47–3.46 0.63
Age 1.01 0.97–1.05 0.60
Indication for catheter insertion:
incident/prevalent renal failure
0.79 0.25–2.53 0.69
ASA use 0.95 0.30–3.04 0.93
LMWH use 5.26 0.86–32.09 0.07
HCH group assignment 3.12 1.08–9.02 0.03
Femoral localization 3.32 0.88–12.57 0.07
Side of catheter insertion 1.33 0.35–4.99 0.67
HGB 1.10 0.83–1.44 0.50
PLT 1.00 0.99–1.01 0.88
FBG 1.00 0.99–1.00 0.15
Baseline APTT 1.13 1.02–1.25 0.02
Baseline INR 0.46 0.01–39.74 0.73
APTT 2 h after catheter insertion 1.03 1.01–1.05 0.002
APTT activated partial thromboplastin time, ASA use of
acetylsalicylic acid, CI confidence interval, FBG fibrinogen,
HCH high concentration of heparin, HGB hemoglobin, INR
international normalized ratio, LMWH use of low molecular
weight heparin, OR odds ratio, PLT platelet count
Table 3 Results of multivariate analysis
Variable OR 95% CI p
Model 1 v2 = 16.85; p = 0.002
HCH assignment 3.64 1.10–12.05 0.03
Baseline APTT 1.12 1.002–1.250 0.04
LMWH use 5.94 0.82–42.88 0.07
Femoral localization 3.12 0.73–13.32 0.12
Model 2 v2 = 19.86; p = 0.0005
APTT 2 h after catheter
insertion
1.03 1.01–1.06 0.01
Baseline APTT 1.10 0.99–1.23 0.07
LMWH use 4.38 0.61–31.55 0.14
Femoral localization 0.72 0.09–5.62 0.75
Model 1 included use of LMWH, site of catheter placement,
baseline APTT value, and group assignment. Model 2 included
instead of group assignment value of APTT 2 h after catheter
insertion
APTT activated partial thromboplastin time, CI confidence
interval, HCH high concentration of heparin, LMWH use of
low molecular weight heparin, OR odds ratio
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Placement of PC into the femoral vein was associated
with bleeding events in our study. Up to our knowledge,
there are no data linking the site of catheter insertion
with the risk of bleeding complications. As in our study
all catheters inserted into the femoral vein were almost
two times longer than those placed in the jugular vein,
the heparin volume was also substantially larger. Thus,
we may assume that the higher amount of heparin leaked
out from the catheter. Indeed, comparison of APTT
prolongation between femoral and jugular catheters
showed a striking difference in the magnitude of clotting
disturbances. This hypothesis was validated by the
results of multivariate analysis. In both models, femoral
localization was not significantly associated with the
primary endpoint. Thus, it seems that the instilled
volume is the culprit of observed associations, but not
the site of catheter insertion.
Another important point to be considered is the
question, does the lower heparin concentration
increase the risk of catheter thrombosis? According
to the obtained results, the risk of catheter thrombosis
was equal between both groups but we have to bear in
mind that the observation period in our study was just
24 h. Noteworthy, it may be speculated based on
earlier data that heparin at a concentration from 1,000
to 2,500 IU/ml is equally effective as heparin used at a
higher concentrations in prevention of catheter throm-
bosis [9, 12]. Thus, it seems that with lower heparin
concentration the same catheter patency is obtained.
The study has potential limitations, such as small
number of studied patients, not blinded design, and
short observation period. Although it is to be under-
lined that during the design of the study the primary
aim was to evaluate the bleeding rates within the
immediate post surgery period as it often prolongs
hospitalization associated with PC placement, utilizes
additional resources, and finally increases the overall
costs. We are aware that a larger trial is needed in order
to draw a final conclusion.
In conclusion, locking of permanent catheters
lumens with heparin at 2,500 IU/ml when compared
to 5,000 IU/ml decreases the risk of bleeding compli-
cations in the post surgery period without compro-
mising their patency.
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